Riprazo (aliskiren)
- Region
- 🇪🇺 EU
- Active substance
- aliskiren
- Company
- Novartis Europharm Ltd.
- Status
- Withdrawn
- Therapeutic area
- Hypertension
- EU approval
- Wed 22 Aug 2007
- Application
- EMEA/H/C/000853
- ATC
- C09XA02
- Official record
- www.ema.europa.eu
Indication
Treatment of essential hypertension.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Rasilez Authorised · Lxo Ireland Designated Activity Company
- 🇪🇺 Rasilez HCT Withdrawn · Noden Pharma DAC
- 🇪🇺 Rasilamlo Withdrawn · Novartis Europharm Ltd
- 🇪🇺 Rasitrio Withdrawn · Novartis Europharm Ltd.
- 🇪🇺 Sprimeo HCT Withdrawn · Novartis Europharm Ltd.
- 🇪🇺 Riprazo HCT Withdrawn · Novartis Europharm Ltd.
- 🇪🇺 Sprimeo Withdrawn · Novartis Europharm Ltd.
- 🇪🇺 Enviage Withdrawn · Novartis Europharm Ltd.
- 🇪🇺 Tekturna Withdrawn · Novartis Europharm Ltd.
Follow Riprazo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.